FPGS1 Antibody

FPGS1 Antibody Characteristics

FPGS1 antibodies target the enzyme responsible for polyglutamylation of folates and antifolate drugs, enhancing their intracellular retention and biochemical activity . Key features include:

Cancer Biomarker Studies

FPGS1 expression correlates with tumor responsiveness to antifolate therapies like pemetrexed. Studies using NN3.2 demonstrated:

• Overexpression in malignancies: 65% of colon adenocarcinoma samples showed 3+ cytoplasmic staining intensity .

• Predictive utility: High FPGS1 levels in tumors may indicate better retention of antifolate drugs, improving chemotherapy efficacy .

Folate Metabolism Regulation

FPGS1 antibodies have identified isoform-specific roles:

• Mitochondrial vs. cytosolic activity: 27616-1-AP confirmed FPGS localization in both compartments, essential for glycine synthesis and nucleotide metabolism .

• Gene modulation effects: FPGS1 inhibition reduced THBS2 and C1S expression by 5.25- and 3.26-fold, respectively, altering extracellular matrix dynamics .

Western Blot Performance

Immunohistochemical Staining Patterns

• Normal tissues: Strong reactivity in colon crypts, liver hepatocytes, and lymphoid cells .

• Malignant tissues: Heterogeneous cytoplasmic staining, with intensity correlating with tumor grade .

Functional Insights from FPGS1 Modulation

Clinical Implications

FPGS1 antibodies are pivotal for:

• Personalized oncology: Stratifying patients for antifolate therapies based on FPGS1 expression levels .

• Drug development: Screening novel antifolates requiring polyglutamylation for activation .